CEPI: the Coalition for Epidemic Preparedness Innovations

CEPI is an innovative global partnership between public, private, philanthropic, and civil society organisations launched in Davos in 2017 to develop vaccines to stop future epidemics. Their mission is to accelerate the development of vaccines against emerging infectious diseases and enable equitable access to these vaccines for people during outbreaks.

CEPI: Broadly protective vaccine against SARS-CoV-2 variants (BPCoV2)

Subsidy: not specified

Total Budget: $200M (for both BPCoV2 and BPBC)

Deadline: 31 May 2021 (Application will require one step, the submission of an Expression of Interest (EOI). An EOI may be submitted at any time and reviews will occur on a bi-monthly rolling basis.)

Project duration: 2 years

Consortium: Single applicant or a consortium are both eligible. This call is open, worldwide, to research and development organisations with expertise in vaccine development (at least one of the partners should have experience in human vaccine development and have a track record of bringing vaccine candidates through to human clinical trials in the past 5 years).

Scope: The main focus of this call is the research and development of novel immunogens for vaccine constructs able to elicit durable broadly protective responses.

Developed vaccine should be a broadly protective vaccine against new emerging variants and variants of concern of the SARS-CoV-2 virus (BPCoV2). Projects should aim to achieve clinical proof-of-concept.

More about CEPI: Broadly protective vaccine against SARS-CoV-2 variants (BPCoV2)

CEPI: Broadly protective Betacoronavirus (BPBC) vaccine

Subsidy: not specified

Total Budget: $200M (for both BPCoV2 and BPBC)

Deadline: 1 October 2021 (Application includes the submission of an Expression of Interest (EOI) and an invitation to submit a full proposal. An EOI may be submitted at any time and reviews will occur on a bi-monthly rolling basis.)

Project duration: 4 years

Consortium: Single applicant or a consortium are both eligible. This call is open, worldwide, to research and development organisations with expertise in vaccine development (at least one of the partners should have experience in human vaccine development and have a track record of bringing vaccine candidates through to human clinical trials in the past 5 years).

Scope: The main focus of this call is the research and development of novel immunogens for vaccine constructs able to elicit durable broadly protective responses.

Developed vaccine should be a broadly protective Betacoronavirus (BPBC) vaccine. Projects should aim to demonstrate clinical proof-of-concept.

More about CEPI: Broadly protective Betacoronavirus (BPBC) vaccine